Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-? agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-? agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.
| Revenue (Most Recent Fiscal Year) | $958.40M |
| Net Income (Most Recent Fiscal Year) | $-288.28M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 9.22 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 19.20 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -27.32% |
| Net Margin (Trailing 12 Months) | -27.32% |
| Return on Equity (Trailing 12 Months) | -50.15% |
| Return on Assets (Trailing 12 Months) | -25.44% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.50 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.16 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.63 |
| Inventory Turnover (Trailing 12 Months) | 0.98 |
| Book Value per Share (Most Recent Fiscal Quarter) | $26.54 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-3.25 |
| Earnings per Share (Most Recent Fiscal Year) | $-12.85 |
| Diluted Earnings per Share (Trailing 12 Months) | $-12.80 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 23.06M |
| Free Float | 19.00M |
| Market Capitalization | $10.44B |
| Average Volume (Last 20 Days) | 0.30M |
| Beta (Past 60 Months) | -1.07 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 17.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.50% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |